


Please type a plus sign (+) inside this box → 

Substitute for FORM 1449A/B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

## **Complete if Known**

Application Number:	10/612,298
Filing Date:	July 2, 2003
First Named Inventor:	Byron E. Anderson
Group Art Unit:	1639
Confirmation Number:	5133
Examiner Name:	Gross, Christopher M.
Attorney Docket Number:	45240-105719

## **U.S. PATENT DOCUMENTS**

Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
	3 3	WO	94/26296		Houghten Pharmaceuticals, Inc.	Nov. 24, 1994		
	3 4	WO	01/39796	A2	Neurochem Inc.	June 7, 2001		

## **OTHER - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
	3 5	Kundu et al., "Combinatorial Approach to Lead Optimization of a Novel Hexapeptide with Antifungal Activity," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10 (16): 1779-1781 (2000).		
	3 6	Copy of Supplementary Partial European Search Report issued in EP 03 76 3093 (2008).		

CHDS01 AOM 463552v1

EXAMINER		DATE CONSIDERED	
----------	--	-----------------	--

\* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).